IL6 and lung carcinoma: In this study, we found that IL6/STAT3 pathway confers resistance to HOXC10 inhibition in KRAS-mutant lung cancer bone metastasis and that activation of p-STAT3Tyr705 further promotes cell survival after HOXC10 inhibition (Fig. 5).